Yichang HEC Changjiang Pharmaceutical (HKG:1558) and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881 (HEC88473) to Apollo Therapeutics Group for $938 million, a Tuesday Hong Kong bourse filing said.
Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881 (HEC88473) while Apollo will have the same rights in the rest of the world for at least 10 years.
Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.